Enveric Biosciences announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI). The compounds span seven distinct molecule classes totaling at least 57 unique product opportunities, all protected by Enveric’s expansive intellectual property portfolio.
